Navigation Links
Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma

Data Presented at the ASCO Cancer Conference

NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today said that data from a follow-up to a Phase 3 multi- national clinical trial shows the combination of DOXIL(R) with VELCADE(R) improves the probability of survival by 41%. The follow-up study also showed no increase in serious side effects such as neuropathy with the addition of DOXIL to the VELCADE. The findings were presented at the American Society of Clinical Oncology (ASCO) global cancer meeting in Chicago.

The VELCADE/DOXIL combination was approved by the FDA just last month as a new treatment option for myeloma patients who have relapsed or who have not responded to at least one other course of treatment. The drugs work in combination because there is evidence that VELCADE increases the effectiveness of DOXIL against cancer cells and DOXIL does the same for VELCADE.

"'Improved survival' are words that every cancer patient wants to hear, and we are encouraged to have this new option to offer patients with peer reviewed data behind it," said Susie Novis, president and co-founder of the IMF. "Until there is a cure, we are moving myeloma toward becoming a chronic disease with long term survival achieved by using drugs in combination and in sequence. The VELCADE/DOXIL combination fits perfectly into this paradigm and offers an important and powerful new opportunity to extend and improve patients' lives."

DOXIL is a specially (liposomal) formulated version of the chemotherapy agent doxorubicin, and is approved for use in other forms of cancer. VELCADE, bortezomib, is approved for myeloma patients who have relapsed or not responded to a previous course of treatment. The findings come from a 14 month follow-up
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Plasma ... of blood products industry. Although the closure of 16 ... major disruption to domestic blood products market, the total ... 2.8% year on year and total lot release volume ... due to stock consumption, insufficient utilization of new plasma ...
(Date:7/11/2014)... Even the hot Texas sun won’t keep ... . The school had previously invested in a ... from APCPLAY, but recently asked for an innovative solution to ... Godley Elementary School chose a Rectangular Shade from APCPLAY as ... on their playground. The shade measures 24’W x 34’H ...
(Date:7/11/2014)... Based in Pearland, Prime Urgent Care has ... County and surrounding counties. Recently, it improved access to ... from Northbound Highway 288 and Feeder Road. , Prime ... get low-cost urgent care of high quality. Although low-cost ... that can match the quality service level of the ...
(Date:7/10/2014)... July 10, 2014 Fatigue, lack ... an increasing number of accidents in the workplace, ... Reboot. The articles highlight safety issues that contribute ... million accidents occur on the job annually, according ... continue to explore "preventable workplace accidents." , Safety ...
(Date:7/10/2014)... July 11, 2014 According to ... Market by Platforms (Land, Airborne, Naval), Application (Software ... & by Geography (North America, Asia-Pacific, Europe, the ... (2014-2019)", published by MarketsandMarkets, the market is estimated ... expected to register a CAGR of 5.56% to ...
Breaking Medicine News(10 mins):Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 3Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 4Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2Health News:Prime Urgent Care Announces New Access to the Clinic, Available from Northbound Highway 288 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4
... artemisinin yield from the herb Artemisia annua by specifying ... ,The two developments could bring down the ... Organization to treat malaria. Over 100 countries use it ... the drug chloroquine. ,A study, published in ...
... Legionnaires’ disease. // ,Jack Russell was admitted to ... of the bacteria Legionella pnuemophila, which causes the disease. ... It takes its name from the first known outbreak, which ... the Pennsylvania Department of the American Legion in 1976. ...
... of Pennsylvania School of Veterinary Medicine have derived uniparental ... eggs or two// sperm - and, for the first ... with healthy cells in adult mice. Their ... in an adult organ and could provide a less ...
... genes associated with the risk of developing Type II ... at risk a step closer. ,Researchers have ... that correspond to a risk of developing this life ... nearly 400,000 mutations in nearly 6,500 people. ...
... composer is just one of many blind people around the ... , Scientists working for the Doheny Eye ... a previous invention released in 2002; a prototype artificial retina. ... its successor, the Argus II Retinal Prosthesis System. ...
... come out with a device which is likely// to ... control issues. ,They have named this ... circuit in spinal cord which is responsible for the ... sustain continence. This device is extremely useful in patients ...
Cached Medicine News:Health News:Scientists Boost Production of Cheap Malaria Drugs 2Health News:Convict Felled by Legionnaires 2Health News:'single–parent' stem cells to replace adult mice organ 2Health News:'single–parent' stem cells to replace adult mice organ 3Health News:Genetic Test for Type II Diabetes Moves Closer 2Health News:Genetic Test for Type II Diabetes Moves Closer 3Health News:Bionic Eye may Restore Sight to the Blind 2Health News:Bladder Pacemaker For Incontinence 2Health News:Bladder Pacemaker For Incontinence 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: